MarketCap
Facebook
X
TelegramAnnual report 2024
added 04-18-2026
Grifols, S.A. P/E Ratio 2011-2026 | GRFS
Annual P/E Ratio Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 31.7 | -638 | -516 | -1.65 K | -1 K | 2.07 | -1.49 K | -2.23 K | -14.5 K | -8.05 K | -4.85 K |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.7 | -14.5 K | -3.17 K |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K |  USA |
 |
BioNTech SE
BNTX
|
6.11 | $ 95.5 | - | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-0.0167 | - | - | $ 269 M | USA |
 |
Edesa Biotech
EDSA
|
-0.985 | $ 15.46 | - | $ 49.4 M | USA |
 |
Esperion Therapeutics
ESPR
|
-24.7 | $ 3.11 | - | $ 646 M | USA |
 |
Exelixis
EXEL
|
15 | $ 44.42 | - | $ 12.1 B | USA |
 |
Fortress Biotech
FBIO
|
11.4 | $ 2.46 | - | $ 68.6 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-17.3 | $ 6.72 | - | $ 192 M | USA |
 |
Galectin Therapeutics
GALT
|
-5.78 | $ 2.23 | - | $ 143 M | USA |
 |
Genprex
GNPX
|
-0.102 | $ 0.89 | - | $ 830 K | USA |
 |
Hutchison China MediTech Limited
HCM
|
26.3 | $ 13.3 | - | $ 11.4 B | China |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
-0.859 | - | - | $ 231 M | USA |
 |
Immuron Limited
IMRN
|
-107 | $ 0.79 | - | $ 8.53 M |  Australia |
 |
INmune Bio
INMB
|
-0.614 | $ 1.54 | - | $ 38.1 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
-56.3 | $ 75.25 | - | $ 12 B | USA |
 |
KalVista Pharmaceuticals
KALV
|
-7.63 | $ 26.71 | - | $ 1.44 B | Britain |
 |
ACADIA Pharmaceuticals
ACAD
|
14.1 | $ 22.35 | - | $ 3.7 B | USA |
 |
Kamada Ltd.
KMDA
|
-121 | $ 8.21 | - | $ 260 M |  Israel |
 |
Kymera Therapeutics
KYMR
|
-25.5 | $ 82.71 | - | $ 6.99 B | USA |
 |
Galapagos NV
GLPG
|
-42.8 | $ 28.39 | - | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-0.489 | $ 3.5 | - | $ 5.76 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
-233 | $ 105.81 | - | $ 5.31 B | USA |
 |
MannKind Corporation
MNKD
|
169 | $ 2.86 | - | $ 874 M | USA |
 |
InflaRx N.V.
IFRX
|
-3.26 | $ 1.97 | - | $ 152 M | Germany |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-0.0913 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-0.146 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-1.98 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-15.8 | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-0.612 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-0.189 | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-213 | $ 23.42 | - | $ 2.98 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-2.17 | - | 3.16 % | $ 1.9 M | USA |
 |
Nanobiotix S.A.
NBTX
|
-5.57 K | $ 34.77 | - | $ 286 B | France |
 |
Ampio Pharmaceuticals
AMPE
|
-0.077 | - | -11.43 % | $ 502 K | USA |